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and ††National Institute for Nanotechnology, Edmonton, Alberta, CanadaABSTRACT Bone morphogenetic proteins (BMPs) play a crucial role during embryonic development and regulate processes
as diverse as neurogenesis, skeletal formation, and hematopoesis. They signal through a hetero-oligomer complex of BMP
receptors. Binding of the ligand to the receptors activates several pathways, including Smad and p38. BMP signaling is
controlled in the extracellular space, the plasma membrane, and the intracellular space; however, the mechanism of receptor
signaling at the plasma membrane and proteins that regulate this process still need to be identified. The experiments presented
here identify the protein kinase casein kinase II (CK2) as a BMP receptor type Ia (BRIa) interacting protein. Fluorescence
resonance energy transfer revealed that this interaction occurs at the plasmamembrane. BMP2 stimulation of C2C12 cells leads
to the release of CK2 from BRIa. Blocking this interaction with specific peptides that inhibit the binding sites for CK2 on BRIa
demonstrated a redistribution of BRIa on the plasma membrane. Signaling was initiated once CK2 was released from BRIa,
leading to the mineralization of C2C12 cells. These data suggest that CK2 is a negative regulator of BMP signaling and
osteoblast differentiation.INTRODUCTIONBone morphogenetic proteins (BMPs) regulate diverse
processes including skeletal formation, embryonic develop-
ment, hematopoesis, and neurogenesis (1,2). They form a
large subgroup of the transforming growth factor-b
(TGF-b) superfamily, consisting of over 20 proteins found
in humans (3). BMP2 is one of the most studied and is
crucial for osteoblast differentiation during healing of
bone fractures (4). BMPs initiate signaling through binding
of two types of receptors, type I and type II, both of which
are serine/threonine kinases. Currently, three type I and
three type II receptors have been identified, of which
BMP receptor type Ia (BRIa) and BMP receptor type II
(BRII) are being extensively investigated. Signaling is initi-
ated with BMPs binding to the high-affinity receptor type I
and then to the type II receptor, a constitutively active kinase
that phosphorylates the type I receptor, which in turn acti-
vates various signaling pathways: Smad, p38, and the Map
kinases (1,5,6).
BMP receptors (BMPRs) are segregated on the plasma
membrane in caveolae and clathrin-coated pits (CCPs)
(7–10). Caveolae are flask-shaped invaginations of the
plasma membrane where proteins are stored or signal
transduction occurs. Two caveolar populations have been
identified; one enriched with the protein caveolin-1 (Cav1)Submitted September 15, 2009, and accepted for publication April 30, 2010.
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of Cav1 (9,11). CCPs are centers for endocytosis of proteins,
including BMPRs (8,12). Both of these domains regulate
BMP signaling, but the mechanism is unclear due to a multi-
tude of conflicting results. Furthermore, BMPRs shuttle to
caveolae enriched with Cav1 a and b, and a fraction of
BRIa shifts to CCPs (7,10). In addition to shuttling between
membrane domains, the organization of BMPRs changes as
well. To date, there are no known proteins involved with the
shuttling and reorganization of BRIa (7,13). Therefore,
novel protein interactions with BRIa were investigated to
determine possible interactions involved with the relocaliza-
tion of BRIa. Casein kinase II (CK2) was identified through
a protein domain search as a possible BRIa-interacting
protein.
CK2 is a highly conserved, ubiquitously expressed
enzyme with >300 substrates affecting many cellular
processes such as cell growth, proliferation, differentiation,
apoptosis, and tumorigenesis (14). It is a tetramer of four
subunits, consisting of two regulatory b-subunits and two
catalytic subunits (a and/or a0) (15). The two b-subunits
aid the assembly of the tetrameric CK2 complex, as well
as recruitment and docking of CK2 substrates (16). The
catalytic activity is targeted to substrates at serine, threo-
nine, and, less favorably, tyrosine residues. Activity is
localized to the membrane-associated cell fractions (17).
The BMP signal is regulated at the membrane surface, yet
this mechanism and the proteins involved are largely
unknown. In the experiments described here, we identified
a novel interaction between BRIa and CK2 at the celldoi: 10.1016/j.bpj.2010.04.070
898 Bragdon et al.surface. Ligand stimulation by BMP2 led to the release of
CK2 from BRIa. Blocking this interaction with specifically
designed peptides resulted in ligand-independent signaling
and osteoblast differentiation. The blocking peptides also
led to a redistribution of BRIa at the cell surface. Taken
together, these results suggest that CK2 negatively regulates
BMP signaling and osteoblast differentiation.MATERIALS AND METHODS
Materials
Recombinant BMP2 was obtained from R&D systems (Minneapolis, MN).
Protein G sepharose was purchased from GE Healthcare (Piscataway, NJ).
Polyclonal goat antisera against BRIa, Alexa 546 conjugated donkey
antigoat IgG, fluorescein isothiocynate conjugated monoclonal mouse
antibody 12CA5 against the HA tag (18), and horseradish peroxidase conju-
gated goat antidonkey IgG were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Horseradish peroxidase goat antirabbit IgG was
purchased from Sigma Aldrich (St. Louis, MO). The cell line C2C12 was
purchased from American Type Culture Collection (Manassas, VA). All
antibodies were tested for specificity as previously reported (19–22). The
HA epitope tag does not affect the activity of the BMP receptors (13,21).
All CK2 mutants were obtained from Dr. Litchfield.Cotransfection of C2C12 cells
Murine myoblast cells (C2C12) were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum (Gemini Bio-Products,
West Sacramento, CA) and 1% penicillin/streptomycin and transfected
either by lipofectamine 2000 (Invitrogen, Carlsbad, CA) for reporter gene
assays or turbofect (Fermentas, Glen Burnie, MD) for western blots.
Plasmids (1 mg) or 200 pM of the small interfering RNA (siRNA) (Santa
Cruz Biotechnology) against the CK2 a-subunit or a random control
(GCUCAGAUCAAUACGGAGAdTdT) was used for transfections.Antibodies
All antibodies were tested for labeling saturation. Fixed cells were labeled
with various concentrations of antibodies, and images were collected.
The fluorescence intensity was then graphed (Fig. S1 A in the Supporting
Material). The antibody concentration corresponding to the region where
the intensity did not change with decreased concentration (Fig. S1 A,
star) was chosen. The region with high antibody concentrations represented
unspecific binding, whereas low antibody concentrations were not effective
in saturating all sites. In addition, we assume that there is a 1:1 ratio for
antibody binding to protein. Labeling of BRIa is shown in Fig. S1 A. Similar
results were seen with the other antibodies.Fluorescence resonance energy transfer
Fluorescence resonance energy transfer (FRET) measures the energy trans-
fer between a donor chromophore on one protein and an acceptor chromo-
phore on another protein (23,24). C2C12 cells were grown and stimulated
with CK2 peptides (40 nM). Subsequent to blocking, BRIa was labeled with
polyclonal goat antibody followed by Alexa 546 donkey antigoat. The CK2
b-subunits were labeled with polyclonal rabbit antibody followed by Alexa
488 goat antirabbit.
Confocal images for FRETwere taken using an Olympus (Melville, NY)
Fluoview 300 equipped with an Ar/Kr (30 mW) mixed gas laser with the
appropriate filter sets for dual fluorophore imaging. Images were taken in
sequential mode at high resolution of 512  512 pixels, with a 63 objec-Biophysical Journal 99(3) 897–904tive at the individual cell surface, removed from the nucleus (Fig. S1 B,
asterisk). The filter was set for 488 nm laser excitation to measure the Alexa
Fluor 488 fluorescence, total laser power was 25.25%, gain (voltage) on the
photomultiplier (PM) was set to 780, and emission was collected between
505 nm and 525 nm. The filter was then shifted to laser excitation of 565 nm
to measure Alexa 546 at 26.25% of total laser power. The PMwas set to 780
and emission was collected with a filter of 585–620 nm. Each image is an
average of four scans with a dwell time of 8 ms/pixel. Forster’s distance for
these fluorophores was calculated to be 32 A˚. FRET was performed as
previously described, with the exception that the acceptor was BRIa and
the donor was CK2 b (7).Image correlation spectroscopy
Confocal images were taken with a Zeiss LSM 510 system equipped
with Ar/Kr (30 mW) and He/Ne (5 mW) lasers. The 568-nm laser excitation
was used at 33% total power to measure Alexa 568, with filters set to
585–620 nm. All images were taken in sequential mode for minimal cross
talk at a high resolution of 512  512 pixels with a 63 objective at the
individual cell surface that is distant from the nucleus. Images were
analyzed by using the family of image correlation spectroscopy (7,25).
Image correlation spectroscopy (ICS) is used to study the distribution of
receptors (26–29). ICS involves autocorrelation analysis of the intensity
fluctuations within confocal images collected from cells that contain
immunofluorescently labeled proteins. Each fluorophore was excited at
the indicated wavelengths and images were taken with the corresponding
filter. The analysis provides a cluster density (CD) value that measures
the average number of receptor clusters/unit area. Sample autocorrelation
function is presented in Fig. S2. The beam width was experimentally







ICS was corrected for white noise and background as described by Petersen
and colleagues (25,31).Knockdown of CK2-a
At 18 h after transfection, cells were fixed and the CK2 a-subunit was im-
munofluorescently labeled using a polyclonal CK2-a antibody, as described
above. The fluorescent signal from individual cells was measured using the
confocal microscope. Background noise was subtracted before normalizing
the data for intensity.Reporter gene assays
Reporter gene assays were performed as described previously (7), except
that 1 mg of plasmids and 200 pM siRNAwere used. Cells were incubated
overnight with 40 nM peptides or 20 nM BMP2.Design of blocking peptides
A prosite search that included patterns with a high probability of occurrence
on BRIa yielded three possible CK2 phosphorylation sites. These sites were
located at amino acids 213–217 (SLKD), 324–328 (SLYD), and 475–479
(SYED). Peptides were designed with the Antennapedia homeodomain
signal sequence for cellular uptake and incorporated one of the following
binding sites: CK2.1 (SYED), CK2.2 (SLYD), or CK2.3 (SLKD). The
peptides also included several amino acid residues flanking each side,
creating a total length of 27 amino acids (CK2.1) and 29 amino acids
(CK2.2 and CK2.3) (32).
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C2C12 cells at 90% confluency in 60-mm dishes were serum-starved for
12 h. Cells were then either stimulated or not stimulated with 40 nM
BMP2 or 100 nM of peptides CK2.1, CK2.2, or CK2.3 for 18 h. Cells
were lysed as described previously, except that 60 mM octyl glucoside
was added, and were normalized for total protein content, which was
measured using Nanodrop (7). Immunoprecipitation (IP) studies used
protein G sepharose, 10 ng/ml of antibody for BRIa, or b-subunits of
CK2. All IPs were performed at room temperature, shaking for 1 h. Samples
were separated on 15% SDS PAGE gel. After electrotransfer of protein to
nitrocellulous membrane, blots were blocked for 30 min with 3% BSA/
TBS-T (Tris-buffered saline with Tween20) at room temperature.
Membranes were blotted for proteins CK2 b or BRIa. As a negative control
for IPs, BRIa blocking peptides (Santa Cruz Biotechnology) were used at a
10-times-higher molar concentration to block the interaction between BRIa
and its corresponding antibody. Loading controls included stripping blots
with Restore Western Blotting Stripping Buffer from Thermo Scientific
(Rockford, IL) and blotting for the immunoprecipitated protein.FIGURE 1 The interaction between BRIa and the CK2 subunit b is
dependent upon BMP2. (Upper) Control and BMP2-stimulated cells were
coimmunoprecipitated for BRIa and blotted for the CK2 b-subunit. The
appearance of a band indicated an association between BRIa and the
CK2 b-subunit. The addition of BMP2 led to a decrease of BRIa-CK2
interaction. As a negative control, blocking peptides (BP) were added
during the IP to block the pull-down of BRIa. There was no CK2 b-subunit
band with the blocking of BRIa pull-down. As for positive controls, blots
were stripped and reprobed for the IP protein. (Lower) The reciprocal of the
upper blot. The blots shown are representative.Von Kossa
After being serum-starved for 12 h, C2C12 cells were stimulated or not
stimulated with 40 nM BMP2, or 100 nM peptides CK2.1, CK2.2, or
CK2.3 for 8 days. The medium was not changed during this time. Cells
were washed with cold phosphate-buffered saline, fixed with 4% parafo-
maldehyde, and incubated with 5% silver nitrate under strong ultraviolet
light for 30 min. After that time cells were washed with water for removal
of silver nitrate and background. Mineralization appeared as a black stain.
Once dried, wells were scanned using an HP scanner, and images were
analyzed with ImageJ. The surface area of the stain was quantified using
the Analyzing Particles function of ImageJ, which can be used to calculate
areas of mineralization. The high-magnification images were taken with
a Nikon (Tokyo, Japan) TMS manual mode 125 with phase 2.Statistics
The mean5 SD and mean5 SE values were calculated from the raw data
at the 95% confidence level. Experiments were performed three times. For
both ICS and FRET measurements, 40 images of individual cells were
taken per slide from three slides.RESULTS
CK2 was identified as a new BRIa-interacting protein
(Fig. 1). C2C12 cells (murine myoblasts), were grown to
a confluency of 90%. After serum starvation, cells were
either stimulated with 40 nM BMP2 or nonstimulated. Cells
were lysed and normalized to total protein content. Anti-
bodies against BRIa or CK2 subunit b were used for co-IP
studies, and the interaction was investigated by western
blot. These experiments revealed that BRIa interacts with
the CK2 subunit b (Fig. 1 upper). Reciprocals showed
similar results (Fig. 1 lower). For negative controls, block-
ing peptides used to inhibit the antibody’s ability to recog-
nize BRIa were added to lysates, followed by IP of BRIa.
No bands were detected for BRIa and CK2 b-subunit.
Fig. 1 also revealed decreased interaction between BRIa
and CK2-b with BMP2 stimulation. The reciprocal did not
show this decreased interaction. All blots were strippedand reprobed for the immunoprecipitated protein to verify
equal pull-down, which was present.Design of peptides blocking the BRIa-CK2
interaction
The CK2 b-subunit interacted with BRIa, and therefore, a
motif search was performed with Prosite to reveal possible
sites for this interaction. The search resulted in three
possible consensus CK2 sequences in the mouse BRIa
(amino acid residues 213–217, 324–328, and 475–479).
Three peptides, each incorporating one amino acid
sequence, were designed (CK2.1, CK2.2, and CK2.3). In
addition to the sequence, these peptides contained the
Antennapedia homeodomain (HD) signal sequence to allow
for enhanced cellular uptake. This HD was used previously
to create a chimera for internalization of a peptide encoding
the caveolin-1 scaffolding domain (32). As a control
peptide, only the HD was used. Serum-starved C2C12 cells
were stimulated with 100 nM CK2 peptides. Cells were
lysed and immunoprecipitated for CK2 subunit b and
BRIa followed by western blot for BRIa and CK2 b-subunit,
respectively. Using this approach, the association of CK2-b
to BRIa was decreased (Fig. 2 A, upper). The reciprocalBiophysical Journal 99(3) 897–904
FIGURE 2 Peptides block the interaction between BRIa and CK2. (A)
Cells were stimulated with the control peptide (HD) or designed peptides
CK2.1, CK2.2, and CK2.3, followed by lysis, normalization of protein
content, and IP with the CK2 b-subunit antibody. Western blots were
probed for BRIa, then stripped and reprobed for CK2 b-subunit as an IP
control. The addition of designed peptides led to a decrease in band inten-
sity. Reciprocal IP is shown in the lower panel. The blots shown are repre-
sentative. (B) Cells stimulated with peptides were fixed and dual-labeled for
BRIa and the CK2 b-subunit, as described earlier. The addition of peptides
resulted in a reduced energy transfer between BRIa and CK2-b. The error
bars depict the SE of five independent experiments (p < 0.05).
FIGURE 3 Blocking of the BRIa-CK2 interaction by peptides led to
Smad-dependent signaling. (A) C2C12 cells were transfected with control
siRNA or with siRNA against the CK2 a-subunit. Cells were then fixed
and immunofluorescently labeled for CK2 a-subunit. The fluorescent signal
was measured using a confocal microscope. CK2-a expression was
downregulated by 40%. The error bars depict the SD (p < 0.05). (B) Cells
transfected with pSBE and pRLuc were incubated with BMP2 or peptides
to block the interaction of BRIa and CK2. For the siRNA luciferase assay,
plasmids encoding pSBE, pRLuc, and the CK2 a-subunit siRNA were
cotransfected. Presence of the peptides or CK2-a siRNA led to BMP-
independent Smad signaling (p < 0.05).
900 Bragdon et al.showed similar results (Fig. 2 A, lower). As controls, blots
were stripped and reblotted for the IP protein.
Since CK2-b is known to bind with its substrates, FRET
was used to determine whether the CK2 peptides inhibited
the interaction between BRIa and CK2-b. FRET measures
the interaction of proteins within 100 A˚ of each other.
Therefore, serum-starved C2C12 cells stimulated with the
peptides were dually immunofluorescently labeled for
BRIa and CK2-b using the primary and secondary anti-
bodies, as described earlier. High-magnification images of
flat regions on the plasma membrane were collected, and
FRET was measured. Fig. 2 B revealed that FRET was
significantly decreased: 75% with the addition of the block-
ing peptides CK2.1 and CK2.3, but only 50% with CK2.2.
Taken together, the BRIa-CK2 interaction was at the
membrane surface, and all three peptides, CK2.1, CK2.2,
and CK2.3, were able to inhibit the BRIa-CK2 interaction.Biophysical Journal 99(3) 897–904Inhibition of the CK2-BRIa interaction led
to the activation of the Smad signaling pathway
The results indicated an interaction between BRIa and the
CK2 b-subunit. In addition, peptides were designed to block
this interaction. To examine whether the CK2-BRIa interac-
tion had a functional role in Smad signaling, reporter gene
assays were performed with the addition of peptides or
siRNA for CK2 a-subunit. The CK2 a-subunit was knocked
down to investigate the role of the catalytic subunit. First,
siRNA against the CK2 a-subunit was used to knock
down the CK2 a-subunit (Fig. 3 A). To achieve this,
C2C12 cells were transfected with siRNA for CK2 a,
control siRNA, or no siRNA. Cells were fixed and fluores-
cently labeled for CK2-a as described before. High-magni-
fication images of flat regions of the membrane were
collected, and the intensity of CK2-a expression on the
cell surface was determined. Fig. 3 A shows the intensity
of CK2-a from the images. There was a 40% downregula-
tion of CK2-a at the cell surface.
To define the effect of the catalytic subunit CK2 a on
BMP signaling, C2C12 cells were transfected with plasmids
encoding the pSBE (Smad binding element fused to firefly
luciferase) and pRLuc (Renilla luciferase plasmid, used for
CK2-b Regulates BMP2 Signaling 901normalization). Cells were transfected with siRNA against
CK2-a, stimulated with peptides CK2.1, CK2.2, or CK2.3
to block the CK2-BRIa interaction, stimulated with BMP2,
or not stimulated. The results (Fig. 3 B) showed a significant
increase in luciferase activity with the addition of BMP2,
peptides, and the knockdown of CK2 a. Peptides CK2.1
and CK2.2 induced the highest level of Smad-dependent
signaling, a 15-fold and 11-fold increase, respectively,
compared to the HD. The knockdown of CK2-a and peptide
CK2.3 each induced a fivefold increase. Thus, the BRIa-
CK2 interaction and availability of catalytic CK2 a-subunit
appeared to negatively affect Smad-dependent signaling.Overexpression of CK2 b-subunit or a dominant
negative CK2 a-subunit led to an increase
in BMP signaling
The downregulation of CK2 interaction with BRIa led to
the increase of BMP signaling. Therefore, the effect of
overexpression of CK2 subunits a and b on BMP signaling
was examined. For this experiment, serum-starved C2C12
cells were transfected with plasmids encoding pSBE and
pRLuc, and plasmids encoding CK2-b, dominant negative
(dn) CK2-a, or CK2-a. Although the dn CK2 a-subunit
has a lysine-to-methionine substitution that renders it
inactive, it is still competent for interactions with other
subunits of CK2. It also shows the same localization within
cells as active CK2 (22,33,34). Fig. 4 shows that the overex-
pression of the CK2 b-subunit and dn CK2-a led to a 100%
increase of Smad-dependent signaling compared to BMP2
stimulation alone. Although there was induction of Smad-
dependent signaling by blocking the interaction of BRIaFIGURE 4 CK2-b influenced Smad-dependent signaling. Cells were
transfected with plasmids encoding pSBE, pRLuc, and, where noted,
CK2-b, dn CK2 a-subunit, or CK2-a. Cells were stimulated with BMP2.
The overexpression of CK2 subunit b and a dn CK2-a significantly
increased Smad-dependent signaling compared to BMP2 stimulation alone.
CK2-a overexpression showed no change. Error bars depict the SD
(p < 0.05).and CK2 b, there was also an increase of signaling with
overexpression of CK2-b and dn CK2-a. CK2-a overexpres-
sion had no effect.Inhibition of the CK2-BRIa interaction led to
a redistribution of BRIa on the plasma membrane
An increase of BMP signaling was seen with the inhibition
of the CK2-BRIa interaction. For Smad-dependent signaling
to occur, BMPRs must shuttle between membrane domains
and change their CD (21). CD is the average number of
protein clusters/unit area of the cell surface. It is possible
that CK2 directs this shuttling or rearrangement of BRIa.
To examine this, serum-starved C2C12 cells were either
stimulated or not stimulated with the CK2 peptides for
18 h. Cells were fixed and labeled for BRIa as described
earlier. High-magnification images were collected from
the flat surface of cells followed by ICS analysis for the
semiquantification of CD (Fig. 5). The results revealed a
25% decrease of CD for BRIa with the addition of peptides
CK2.1 and CK2.3. Peptide CK2.2 led to a decrease of 20%.
This is similar to the decrease observed with BMP2 stimu-
lation. The overall intensity of BRIa at the cell surface
showed no difference between treatments (data not shown).Block of the BRIa-CK2 interaction led
to mineralization
The previous results showed that BRIa interacted with CK2
on the plasma membrane. The blocking of this interactionFIGURE 5 Cluster density is affected by the BRIa-CK2 interaction.
C2C12 cells were stimulated with HD, CK2.1, CK2.2, or CK2.3 for 18 h,
then fixed and labeled for BR1a. ICS analysis revealed that the BRIa CD
decreased 20% with peptide CK2.2 and 25% with peptides CK2.1 and
CK2.3. Error bars depict the SD (p < 0.05).
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902 Bragdon et al.led to the activation of Smad-dependent signaling. Further,
the peptides redirected the BRIa to a different location
on the plasma membrane. Overexpression of the CK2
b-subunit and the dn CK2 a-subunit increased Smad-depen-
dent signaling in the presence of BMP2. To investigate
whether the loss of CK2 interaction with BRIa can lead to
mineralization by C2C12 cells, serum-starved cells were
incubated with peptides or BMP2 for 8 days. Cells were
fixed and von Kossa staining was performed as described
in Materials and Methods. Mineralization was analyzed
with ImageJ (Fig. 6 A) and light microscopy (Fig. 6 B).
The results show an increased amount of mineralization in
response to peptide treatment, comparable to mineralization
obtained by 40 nM BMP2.DISCUSSION
Activation of BMP signaling pathways requires that both
BMPRs, type I and type II, shuttle between caveolae and
CCPs, along with receptor reorganization on the membrane
surface (7,8,10,21). The mechanism of BMPR organizationFIGURE 6 Mineralization is induced by blocking the BRIa-CK2 interac-
tion. C2C12 cells were incubated with BMP2 or 100 nM peptides. Cells
were fixed and subjected to von Kossa staining for mineralization. (A)
Addition of BMP2 led to a significant increase in the area of mineralization
(p < 0.05). The addition of peptides increased mineralization in a manner
equivalent to that seen with BMP2 stimulation. Error bars depict the SE. (B)
A representative low- and high-magnification light field image of the
mineralization.
Biophysical Journal 99(3) 897–904and shuttling at the cell surface is still poorly understood,
partly due to the limited identification of proteins that
interact with BMPRs. Here, evidence is presented that
establishes an interaction between BRIa and CK2 and the
novel regulatory role of this interaction in Smad-dependent
signaling.
The tetramer of CK2 is composed of two regulatory and
substrate-binding subunits (b) and two active kinase
subunits (a and/or a0). Initially, the b-subunit was investi-
gated due to its binding abilities. BRIa and the b-subunit
of CK2 interacted in the absence of BMP2. An interaction
also has been demonstrated between the CK2 b-subunit
and ALK-1 (activinlike receptor-1) (35). Stimulation with
BMP2 caused a release of the CK2 b-subunit from BRIa,
as demonstrated with the co-IP by the antibody to BRIa,
yet the reciprocal did not show this release. These results
indicated two possible conclusions: 1), there is more than
one CK2 b-subunit binding to a single BRIa; or 2), not all
proteins were immunoprecipitated. A motif search did in
fact yield three possible sites for CK2 phosphorylation of
BRIa.
Peptides were created to specifically block each of the
interacting sites. It is important to note that the peptides
block the association by binding to CK2-b, not to BRIa. It
is possible that these peptides have other effects, but western
blots and FRET verified that the three designed peptides
blocked the interaction of BRIa and CK2 b at the cell
surface. Co-IP and FRET demonstrated that peptides
CK2.1 and CK2.3 exerted the highest blocking function.
The Smad pathway is the most intensively studied of the
BMP signaling pathways. Activation of Smad is initiated
with the binding of BMP to BRIa and BRII preformed
receptor complexes. BRII phosphorylates BRIa, activating
the kinase activity of BRIa. Smads 1/5/8 are then phosphor-
ylated by BRIa and form complexes with Smad4 to translo-
cate the nucleus where it regulates gene transcription (36).
Reporter gene assays were used to examine the effects of
the blocking peptides on this pathway. The three blocking
peptides induced Smad signaling. The greatest increase
was observed with peptide CK2.1. These data signify that
CK2 b-subunits are negative regulators of Smad signaling.
The activation of the Smad pathway occurred in the absence
of BMP2, indicating that signaling is not dependent on
ligand binding but on the assembly/disassembly of regula-
tory proteins on the cellular membrane. However, the possi-
bility that CK2 influences the phosphorylation state of
BRIa, and that BMP signaling is regulated through this,
cannot be ruled out.
CK2-b has been shown to enhance BMP signaling
through its interaction with ALK-1 (35). The discrepancy
could be due to the use of diverse cell types or investigation
of different TGF-b superfamily receptors. The mode of
signaling differs between BMPRs and TGF-b receptors.
The active hetero-oligomer of TGF-b receptors shuttles to
CCPs for endocytosis, where signaling occurs (12). This is
FIGURE 7 BMP signaling model including CK2-b. Shown here is an
incorporation of CK2-b with the model for activation of BMP signaling.
CK2-b (gray ovals) binds to preformed complexes of BRIa and BRII. There
is a release of CK2-b from BRIa upon stimulation of BMP2 (pentagons).
BRII phosphorylates BRIa, and BRIa then phosphorylates Smad 1/5/8.
Smad4 forms a complex with phosphorylated Smad1/5/8 and translocates
to the nucleus, where it regulates gene transcription and downstream effects
(which would include mineralization).
CK2-b Regulates BMP2 Signaling 903not seen with BMP signaling; the receptors signal at the cell
surface (8). To address these differences, overexpression
studies similar to that used by Lee et al. were utilized
with C2C12 cells. Stimulation by BMP2 plus either overex-
pression of CK2 b-subunit or a dn form of CK2 a-subunit
both led to enhanced BMP Smad-dependent signaling and
decreased CK2-a colocalization with BRIa. The signaling
results were in agreement with those of Lee et al.
Not only is signaling initiated with BMP2 stimulation, but
the CD of BRIa decreases, an indication of protein aggrega-
tion. This decrease is not due to internalization, because the
cell surface receptor intensity is unchanged (21). Blocking
the interaction of BRIa and CK2-b with the three peptides
led to elevated BMP signaling independent of BMP2 stimu-
lation. Therefore, the CD of BRIa in cells treated with
peptides was examined. The blocking peptides initiated an
aggregation of BRIa. Peptides CK2.1 and CK2.3 presented
the greatest degree of aggregation. Although the CK2
peptides bind to the CK2 b-subunit and not BRIa, their
effects are related to CD and mediated through the Smad
pathway. This suggests that the CK2 b-subunit is a novel
protein involved with the mechanism of receptor organiza-
tion at the cell surface.
Inhibiting the BRIa-CK2 interaction led to receptor
aggregation and signaling that is comparable to BMP2
stimulation. In C2C12 cells, BMP2 initiates osteoblastdifferentiation (37). It is possible that the blocking peptides
could also induce osteoblast differentiation. A marker used
for mature osteoblasts is mineralization, measured by von
Kossa staining (38). The addition of BMP2 or the blocking
peptides induced mineralization that was significantly
higher than in nonstimulated and HD peptide, indicating
that CK2 b-subunit/BRIa interaction can also regulate
osteoblast differentiation.
In conclusion, it was demonstrated in this study that 1), the
CK2 b-subunits interact with BRIa and are released upon
BMP2 stimulation; 2), custom-designed peptides blocked
this interaction; 3), blocking this interaction in the presence
of the blocking peptides led to aggregation of BRIa; and 4),
prevention of the CK2-BRIa interaction with the peptides
activated the Smad pathway and induced osteoblast differen-
tiation. Fig. 7 is a model depicting CK2 influence on BMP
signaling. The CK2 b-subunit binds to the preformed
complex of BMPRs. Upon BMP2 stimulation, CK2-b is
released from BRIa. BRII phosphorylates BRIa, and in turn
BRIa phosphorylates Smad1/5/8. The phosphorylated
Smads form a complex with Smad4 that translocates to the
nucleus, where it regulates gene transcription. These data
suggest that the CK2 b-subunit is a novel regulator of
BMPR signaling and the cell surface organization of BRIa.SUPPORTING MATERIAL
Two figures are available at http://www.biophysj.org/biophysj/supplemental/
S0006-3495(10)00620-X.
We express our sincere appreciation to Drs. Wesley Beamer, Clifford
Rosen, and Robert Gundersen for their support and guidance, to Betty
Ingraham, Jeremy Bonor, and James Cook for laboratory support and
advice, and to JoAnne Julian for her time spent reading the manuscript
and her helpful suggestions.REFERENCES
1. Chen, D., M. Zhao, and G. R. Mundy. 2004. Bone morphogenetic
proteins. Growth Factors. 22:233–241.
2. Kawai, M., H. Hattori,., T. Hoshino. 1994. Development of hemopoi-
etic bone marrow within the ectopic bone induced by bone morphoge-
netic protein. Blood Cells. 20:191–199; discussion, 200–191.
3. Raida, M., A. C. Heymann, ., D. Niederwieser. 2006. Role of bone
morphogenetic protein 2 in the crosstalk between endothelial progen-
itor cells and mesenchymal stem cells. Int. J. Mol. Med. 18:735–739.
4. Tsuji, K., A. Bandyopadhyay, ., V. Rosen. 2006. BMP2 activity,
although dispensable for bone formation, is required for the initiation
of fracture healing. Nat. Genet. 38:1424–1429.
5. ten Dijke, P., H. Ichijo, ., K. Miyazono. 1993. Activin receptor-like
kinases: a novel subclass of cell-surface receptors with predicted
serine/threonine kinase activity. Oncogene. 8:2879–2887.
6. Nohe, A., S. Hassel,., P. Knaus. 2002. The mode of bone morphoge-
netic protein (BMP) receptor oligomerization determines different
BMP-2 signaling pathways. J. Biol. Chem. 277:5330–5338.
7. Bragdon, B., S. Thinakaran, ., A. Nohe. 2009. FRET reveals novel
protein-receptor interaction of bone morphogenetic proteins receptors
and adaptor protein 2 at the cell surface. Biophys. J. 97:1428–1435.Biophysical Journal 99(3) 897–904
904 Bragdon et al.8. Hartung, A., K. Bitton-Worms,., P. Knaus. 2006. Different routes of
bone morphogenic protein (BMP) receptor endocytosis influence BMP
signaling. Mol. Cell. Biol. 26:7791–7805.
9. Nohe, A., E. Keating, ., N. O. Petersen. 2004. Caveolin-1 isoform
reorganization studied by image correlation spectroscopy. Faraday
Discuss. 126:185–195; discussion, 245–154.
10. Nohe, A., E. Keating, ., N. O. Petersen. 2005. Dynamics and
interaction of caveolin-1 isoforms with BMP-receptors. J. Cell Sci.
118:643–650.
11. Fujimoto, T., H. Kogo, ., T. Une. 2000. Isoforms of caveolin-1 and
caveolar structure. J. Cell Sci. 113:3509–3517.
12. Di Guglielmo, G. M., C. Le Roy, ., J. L. Wrana. 2003. Distinct
endocytic pathways regulate TGF-b receptor signalling and turnover.
Nat. Cell Biol. 5:410–421.
13. Gilboa, L., A. Nohe,., P. Knaus. 2000. Bone morphogenetic protein
receptor complexes on the surface of live cells: a new oligomerization
mode for serine/threonine kinase receptors. Mol. Biol. Cell. 11:
1023–1035.
14. Duncan, J. S., and D. W. Litchfield. 2008. Too much of a good thing:
the role of protein kinase CK2 in tumorigenesis and prospects for
therapeutic inhibition of CK2. Biochim. Biophys. Acta. 1784:33–47.
15. Litchfield, D. W. 2003. Protein kinase CK2: structure, regulation and
role in cellular decisions of life and death. Biochem. J. 369:1–15.
16. Vilk, G., J. E. Weber, ., D. W. Litchfield. 2008. Protein kinase CK2
catalyzes tyrosine phosphorylation in mammalian cells. Cell. Signal.
20:1942–1951.
17. Litchfield, D. W., E. Slominski, ., R. D. Gietz. 1996. Analysis of
interactions between the subunits of protein kinase CK2. Biochem.
Cell Biol. 74:541–547.
18. Wilson, I. A., H. L. Niman,., R. A. Lerner. 1984. The structure of an
antigenic determinant in a protein. Cell. 37:767–778.
19. Gietz, R. D., K. C. Graham, and D. W. Litchfield. 1995. Interactions
between the subunits of casein kinase II. J. Biol. Chem. 270:
13017–13021.
20. Graham, K. C., and D. W. Litchfield. 2000. The regulatory b subunit of
protein kinase CK2 mediates formation of tetrameric CK2 complexes.
J. Biol. Chem. 275:5003–5010.
21. Nohe, A., E. Keating,., N. O. Petersen. 2003. Effect of the distribu-
tion and clustering of the type I A BMP receptor (ALK3) with the type
II BMP receptor on the activation of signalling pathways. J. Cell Sci.
116:3277–3284.
22. Penner, C. G., Z. Wang, and D. W. Litchfield. 1997. Expression and
localization of epitope-tagged protein kinase CK2. J. Cell. Biochem.
64:525–537.
23. Sorkin, A., M. McClure, ., R. Carter. 2000. Interaction of EGF
receptor and grb2 in living cells visualized by fluorescence resonance
energy transfer (FRET) microscopy. Curr. Biol. 10:1395–1398.Biophysical Journal 99(3) 897–90424. Kenworthy, A. K. 2001. Imaging protein-protein interactions using
fluorescence resonance energy transfer microscopy. Methods.
24:289–296.
25. Nohe, A., and N. O. Petersen. 2007. Image correlation spectroscopy.
Sci. STKE. 2007:pl7.
26. Brown, C. M., and N. O. Petersen. 1998. An image correlation analysis
of the distribution of clathrin associated adaptor protein (AP-2) at the
plasma membrane. J. Cell Sci. 111:271–281.
27. Srivastava, M., and N. O. Petersen. 1998. Diffusion of transferrin
receptor clusters. Biophys. Chem. 75:201–211.
28. Wiseman, P. W., P. Hoddelius,., K. E. Magnusson. 1997. Aggregation
of PDGF-b receptors in human skin fibroblasts: characterization by
image correlation spectroscopy (ICS). FEBS Lett. 401:43–48.
29. Wiseman, P. W., and N. O. Petersen. 1999. Image correlation spectros-
copy. II. Optimization for ultrasensitive detection of preexisting
platelet-derived growth factor-b receptor oligomers on intact cells.
Biophys. J. 76:963–977.
30. Reference deleted in proof.
31. Keating, E., C. M. Brown, and N. O. Petersen. 2005. Mapping
molecular interactions and transport in cell membranes by image corre-
lation spectroscopy. In Molecular Imaging: FRET Microscopy and
Spectroscopy. A. Periasamy and R. Day, editors. (Oxford University
Press. 284–302.
32. Zhu, L., D. Schwegler-Berry, ., P. He. 2004. Internalization of
caveolin-1 scaffolding domain facilitated by Antennapedia homeodo-
main attenuates PAF-induced increase in microvessel permeability.
Am. J. Physiol. Heart Circ. Physiol. 286:H195–H201.
33. Canton, D. A., C. Zhang, and D. W. Litchfield. 2001. Assembly of
protein kinase CK2: investigation of complex formation between
catalytic and regulatory subunits using a zinc-finger-deficient mutant
of CK2b. Biochem. J. 358:87–94.
34. Vilk, G., R. B. Saulnier,., D. W. Litchfield. 1999. Inducible expres-
sion of protein kinase CK2 in mammalian cells. Evidence for
functional specialization of CK2 isoforms. J. Biol. Chem. 274:
14406–14414.
35. Lee, N. Y., J. C. Haney,., G. C. Blobe. 2009. Casein kinase 2b as a
novel enhancer of activin-like receptor-1 signaling. FASEB J. 23:
3712–3721.
36. Nishimura, R., K. Hata, ., T. Yoneda. 2003. The role of Smads in
BMP signaling. Front. Biosci. 8:s275–s284.
37. Katagiri, T., A. Yamaguchi, ., T. Suda. 1994. Bone morphogenetic
protein-2 converts the differentiation pathway of C2C12 myoblasts
into the osteoblast lineage. J. Cell Biol. 127:1755–1766.
38. Wang, Y. H., Y. Liu, ., D. W. Rowe. 2006. Examination of mineral-
ized nodule formation in living osteoblastic cultures using fluorescent
dyes. Biotechnol. Prog. 22:1697–1701.
